News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transition Therapeutics Inc. (TTH.TO) Study on Type 2 Diabetes Better Than Expected



4/30/2013 9:21:21 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Transition Therapeutics Inc said an early-stage study of its experimental type 2 diabetes drug showed significant improvement in blood sugar control and reductions in body weight, sending its shares up more than 65 percent. A once-weekly administered dose of the drug, codenamed TT-401, showed an acceptable safety and tolerability profile for all doses. The drug was tested in five doses on diabetic patients and in one dose on non-diabetic obese patients, the company said.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at RTT News
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES